Skip to content

AYTU BIOPHARMA, INC: 10-Q filed 2018-05-14

What AYTU BIOPHARMA, INC reported in its quarterly report filed 2018-05-14 (fiscal Q3 2018): 37 published measures, 94 facts as tagged in accession 0001213900-18-006106.

This filing

Form
10-Q (quarterly report)
Filed
2018-05-14
Fiscal period
fiscal Q3 2018
Accession
0001213900-18-006106 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYTU BIOPHARMA, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-03-3123,374,715USD
At 2017-06-3014,998,517USD
At 2017-03-3115,917,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-03-3110,624,388USD
At 2017-06-3010,998,701USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-03-3112,750,327USD
At 2017-06-303,999,816USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-03-3112,006,069USD
At 2017-06-30802,328USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-03-31-2,817,712USD90
2017-07-01 to 2018-03-31-10,735,432USD274
2017-01-01 to 2017-03-31-5,216,342USD90
2016-07-01 to 2017-03-31-15,757,916USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-07-01 to 2018-03-3174,707USD274
2016-07-01 to 2017-03-3153,435USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-01-01 to 2018-03-31607,473USD90
2017-07-01 to 2018-03-312,734,995USD274
2017-01-01 to 2017-03-31893,548USD90
2016-07-01 to 2017-03-312,385,701USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-03-31-79,805,161USD
At 2017-06-30-69,069,729USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-10-01 to 2017-12-316,600,000USD92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-03-31260,742USD
At 2017-06-30647,254USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-07-01 to 2018-03-31288,010USD274
2016-07-01 to 2017-03-312,241,989USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-03-31-7,524,622USD90
2017-07-01 to 2018-03-31-15,874,601USD274
2017-01-01 to 2017-03-31-4,859,827USD90
2016-07-01 to 2017-03-31-15,025,019USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-03-3114,594,992USD
At 2017-06-303,028,562USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-01-01 to 2018-03-31186,629USD90
2017-07-01 to 2018-03-31572,155USD274
2017-01-01 to 2017-03-3180,722USD90
2016-07-01 to 2017-03-31884,187USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-03-314,341,905USD
At 2017-06-303,610,468USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-03-313,199,323USD
At 2017-06-302,220,400USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2017-06-30238,426USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2018-03-31252,278USD
At 2017-06-30271,278USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2018-03-31732,476USD
At 2017-06-30528,039USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-01-01 to 2018-03-318,132,095USD90
2017-07-01 to 2018-03-3118,609,596USD274
2017-01-01 to 2017-03-315,753,375USD90
2016-07-01 to 2017-03-3117,410,720USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2018-03-31883,820USD
At 2017-06-301,312,221USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2018-01-01 to 2018-03-311,136,833USD90
2017-07-01 to 2018-03-311,809,445USD274
2017-01-01 to 2017-03-31324,438USD90
2016-07-01 to 2017-03-311,067,654USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2018-01-01 to 2018-03-314,637,495USD90
2017-07-01 to 2018-03-3113,809,264USD274
2017-01-01 to 2017-03-314,385,145USD90
2016-07-01 to 2017-03-3113,732,226USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-01-01 to 2018-03-31114,141USD90
2017-07-01 to 2018-03-31-22,391USD274
2017-01-01 to 2017-03-31279,049USD90
2016-07-01 to 2017-03-31774,526USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-03-3135,820,069shares
At 2017-06-30824,831shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2018-03-3112,081,797USD
At 2017-06-30877,542USD
At 2017-03-313,545,265USD
At 2016-06-308,054,190USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-03-3192,551,906USD
At 2017-06-3073,069,463USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-03-31498,000USD
At 2017-06-30246,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-03-318,242,029USD
At 2017-06-309,231,072USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-03-31211,415USD
At 2017-06-30782,536USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-03-31896,899USD
At 2017-06-30310,760USD

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2017-07-01 to 2018-03-311,975,448USD274
2016-07-01 to 2017-03-312,263,975USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2018-01-01 to 2018-03-31387,606USD90
2017-07-01 to 2018-03-311,157,258USD274
2017-01-01 to 2017-03-31437,013USD90
2016-07-01 to 2017-03-311,311,043USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-01-01 to 2018-03-314,706,910USD90
2017-07-01 to 2018-03-315,139,169USD274
2017-01-01 to 2017-03-31-356,515USD90
2016-07-01 to 2017-03-31-732,897USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-07-01 to 2017-03-31631,481USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-07-01 to 2018-03-31204,437USD274
2016-07-01 to 2017-03-31180,110USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-07-01 to 2018-03-31-428,401USD274
2016-07-01 to 2017-03-31-290,984USD274

Inspect the source

Entity
AYTU BIOPHARMA, INC / CIK 0001385818
Captured
SEC response SHA-256
3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))